← All trials
NCT03501979
Phase 2Interventional
Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Oct 31, 2018
- Primary completion
- Sep 30, 2022
- Completion date
- Sep 30, 2023
- First posted
- —
- Last posted
- —
- Enrollment
- 30
- Arms / groups
- 1 / —
- Source
- AACT · ingestion pipeline
Sponsors
- University of Alabama, BirminghamLead sponsor
- Seattle GeneticsCollaborator
- Georgetown UniversityCollaborator
- University of WashingtonCollaborator
- Indiana UniversityCollaborator
- Johns Hopkins UniversityCollaborator
- University of MichiganCollaborator
- University of California, San FranciscoCollaborator
- University of ChicagoCollaborator
- University of Texas at HoustonStudy chair
- University of Texas, GalvestonCollaborator
- University of Alabama, BirminghamOverall official - principal investigator
- University of Alabama, BirminghamReponsible party - principal investigator
- Translational Breast Cancer Research ConsortiumCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.